Reciprocal tumor-platelet interaction through the EPHB1-EFNB1 axis in the liver metastatic niche promotes metastatic tumor outgrowth in pancreatic ductal adenocarcinoma

Abstract

Background: The interaction between the metastatic microenvironment and tumor cells plays an important role in metastatic tumor formation. Platelets play pivotal roles in hematogenous cancer metastasis through tumor cell-platelet interaction in blood vessels. Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy distinguished by its notable tendency to metastasize to the liver. However, the role of platelet in the liver metastatic niche of PDAC remains elusive. This study aimed to elucidate the role of platelets and their interactions with tumor cells in the liver metastatic niche of PDAC.

Methods: An mCherry niche-labeling system was established to identify cells in the liver metastatic niche of PDAC. Platelet depletion in a liver metastasis mouse model was used to observe the function of platelets in PDAC liver metastasis. Gain-of-function and loss-of-function of erythropoietin-producing hepatocellular receptor B1 (Ephb1), tumor cell-platelet adhesion, recombinant protein, and tryptophan hydroxylase 1 (Tph1)-knockout mice were used to study the crosstalk between platelets and tumor cells in the liver metastatic niche.

Results: The mCherry metastatic niche-labeling system revealed the presence of activated platelets in the liver metastatic niche of PDAC patients. Platelet depletion decreased liver metastatic tumor growth in mice. Mechanistically, tumor cell-expressed EPHB1 and platelet-expressed Ephrin B1 (EFNB1) mediated contact-dependent activation of platelets via reverse signaling-mediated AKT signaling activation, and in turn, activated platelet-released 5-HT, further enhancing tumor growth.

Conclusion: We revealed the crosstalk between platelets and tumor cells in the liver metastatic niche of PDAC. Reciprocal tumor-platelet interaction mediated by the EPHB1-EFNB1 reverse signaling promoted metastatic PDAC outgrowth via 5-HT in the liver. Interfering the tumor-platelet interaction by targeting the EPHB1-EFNB1 axis may represent a promising therapeutic intervention for PDAC liver metastasis.

Keywords

Liver metastatic niche / Tumor-platelet interaction / Axon guidance molecule / Reverse signaling / 5-HT

References

[1] Celia-Terrassa T, Kang Y. Metastatic niche functions and therapeutic opportunities. Nat Cell Biol. 2018; 20(8): 868-77.

[2] Massague J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016; 529(7586): 298-306.

[3] Obenauf AC, Massague J. Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer. 2015; 1(1): 76-91.

[4] Ganesh K, Massague J. Targeting metastatic cancer. Nat Med. 2021; 27(1): 34-44.

[5] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024; 74(1): 12-49.

[6] Kamisawa T, Isawa T, Koike M, Tsuruta K, Okamoto A. Hematogenous metastases of pancreatic ductal carcinoma. Pancreas. 1995; 11(4): 345-9.

[7] Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350(12): 1200-10.

[8] Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997; 21(2): 195-200.

[9] Yang J, Lin P, Yang M, Liu W, Fu X, Liu D, et al. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic ductal adenocarcinoma. Genome Biol. 2021; 22(1): 4.

[10] Makohon-Moore AP, Zhang M, Reiter JG, Bozic I, Allen B, Kundu D, et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet. 2017; 49(3): 358-66.

[11] Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010; 467(7319): 1109-13.

[12] Yang M, Zhang C. The role of liver sinusoidal endothelial cells in cancer liver metastasis. Am J Cancer Res. 2021; 11(5): 1845-60.

[13] Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D’Angelica MI, Endo I, et al. Liver metastases. Nat Rev Dis Primers. 2021; 7(1): 27.

[14] Gremmel T, Frelinger AL, 3rd, Michelson AD. Platelet Physiology. Semin Thromb Hemost. 2016; 42(3): 191-204.

[15] Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015; 126(5): 582-8.

[16] Sitia G, Aiolfi R, Di Lucia P, Mainetti M, Fiocchi A, Mingozzi F, et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci U S A. 2012; 109(32): E2165-72.

[17] Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010; 28(9): 1467-72.

[18] Rachidi S, Wallace K, Day TA, Alberg AJ, Li Z. Lower circulating platelet counts and antiplatelet therapy independently predict better outcomes in patients with head and neck squamous cell carcinoma. J Hematol Oncol. 2014; 7: 65.

[19] Ma C, Fu Q, Diggs LP, McVey JC, McCallen J, Wabitsch S, et al. Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD. Cancer Cell. 2022; 40(9): 986-98 e5.

[20] Yin JB, Wang X, Zhang X, Liu L, Wang RT. Mean platelet volume predicts survival in pancreatic cancer patients with synchronous liver metastases. Sci Rep. 2018; 8(1): 6014.

[21] Jonnalagadda D, Izu LT, Whiteheart SW. Platelet secretion is kinetically heterogeneous in an agonist-responsive manner. Blood. 2012; 120(26): 5209-16.

[22] Italiano JE, Jr., Richardson JL, Patel-Hett S. Battinelli E, Zaslavsky A, Short S, et al. Angiogenesis is regulated by a novel mechanism: pro-and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 2008; 111(3): 1227-33.

[23] Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, et al. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A. 2005; 102(1): 216-20.

[24] Chen X, Xu Y, Chen Q, Zhang H, Zeng Y, Geng Y, et al. The phosphatase PTEN links platelets with immune regulatory functions of mouse T follicular helper cells. Nat Commun. 2022; 13(1): 2762.

[25] Heijnen H, van der Sluijs P. Platelet secretory behaviour: as diverse as the granules … or not? J Thromb Haemost. 2015; 13(12): 2141-51.

[26] Balakrishna P, George S, Hatoum H, Mukherjee S. Serotonin Pathway in Cancer. Int J Mol Sci. 2021; 22(3): 1268.

[27] Jiang SH, Li J, Dong FY, Yang JY, Liu DJ, Yang XM, et al. Increased Serotonin Signaling Contributes to the Warburg Effect in Pancreatic Tumor Cells Under Metabolic Stress and Promotes Growth of Pancreatic Tumors in Mice. Gastroenterology. 2017; 153(1): 277-91 e19.

[28] Wang X, Hu LP, Qin WT, Yang Q, Chen DY, Li Q, et al. Identification of a subset of immunosuppressive P2RX1-negative neutrophils in pancreatic cancer liver metastasis. Nat Commun. 2021; 12(1): 174.

[29] Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, et al. Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015; 47(10): 1168-78.

[30] Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14: 7.

[31] Ombrato L, Nolan E, Kurelac I, Mavousian A, Bridgeman VL, Heinze I, et al. Metastatic-niche labelling reveals parenchymal cells with stem features. Nature. 2019; 572(7771): 603-8.

[32] Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012; 9(7): 671-5.

[33] Jiang SH, Zhu LL, Zhang M, Li RK, Yang Q, Yan JY, et al. GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca(2+) signalling in a GABA-independent manner. Gut. 2019; 68(11): 1994-2006.

[34] van der Heyde HC, Gramaglia I, Sun G, Woods C. Platelet depletion by anti-CD41 (alphaIIb) mAb injection early but not late in the course of disease protects against Plasmodium berghei pathogenesis by altering the levels of pathogenic cytokines. Blood. 2005; 105(5): 1956-63.

[35] Prevost N, Woulfe DS, Tognolini M, Tanaka T, Jian W, Fortna RR, et al. Signaling by ephrinB1 and Eph kinases in platelets promotes Rap1 activation, platelet adhesion, and aggregation via effector pathways that do not require phosphorylation of ephrinB1. Blood. 2004; 103(4): 1348-55.

[36] Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008; 133(1): 38-52.

[37] Grandi A, Zini I, Palese S, Giorgio C, Tognolini M, Marchesani F, et al. Targeting the Eph/Ephrin System as Anti-Inflammatory Strategy in IBD. Front Pharmacol. 2019; 10: 691.

[38] Barquilla A, Pasquale EB. Eph receptors and ephrins: therapeutic opportunities. Annu Rev Pharmacol Toxicol. 2015; 55: 465-87.

[39] Riedl SJ, Pasquale EB. Targeting the Eph System with Peptides and Peptide Conjugates. Curr Drug Targets. 2015; 16(10): 1031-47.

[40] Haimovich B, Lipfert L, Brugge JS, Shattil SJ. Tyrosine phosphorylation and cytoskeletal reorganization in platelets are triggered by interaction of integrin receptors with their immobilized ligands. J Biol Chem. 1993; 268(21): 15868-77.

[41] Kroner C, Eybrechts K, Akkerman JW. Dual regulation of platelet protein kinase B. J Biol Chem. 2000; 275(36): 27790-8.

[42] Barry FA, Gibbins JM. Protein kinase B is regulated in platelets by the collagen receptor glycoprotein VI. J Biol Chem. 2002; 277(15): 12874-8.

[43] Banfic H, Downes CP, Rittenhouse SE. Biphasic activation of PKBalpha/Akt in platelets. Evidence for stimulation both by phosphatidylinositol 3, 4-bisphosphate, produced via a novel pathway, and by phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem. 1998; 273(19): 11630-7.

[44] Li Z, Zhang G, Marjanovic JA, Ruan C, Du X. A platelet secretion pathway mediated by cGMP-dependent protein kinase. J Biol Chem. 2004; 279(41): 42469-75.

[45] Randriamboavonjy V, Schrader J, Busse R, Fleming I. Insulin induces the release of vasodilator compounds from platelets by a nitric oxide-G kinase-VAMP-3-dependent pathway. J Exp Med. 2004; 199(3): 347-56.

[46] Flevaris P, Li Z, Zhang G, Zheng Y, Liu J, Du X. Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. Blood. 2009; 113(4): 893-901.

[47] Roweth HG, Battinelli EM. Lessons to learn from tumor-educated platelets. Blood. 2021; 137(23): 3174-80.

[48] Arvanitis D, Davy A. Eph/ephrin signaling: networks. Genes Dev. 2008; 22(4): 416-29.

[49] Prevost N, Woulfe DS, Jiang H, Stalker TJ, Marchese P, Ruggeri ZM, et al. Eph kinases and ephrins support thrombus growth and stability by regulating integrin outside-in signaling in platelets. Proc Natl Acad Sci U S A. 2005; 102(28): 9820-5.

[50] Berrou E, Soukaseum C, Favier R, Adam F, Elaib Z, Kauskot A, et al. A mutation of the human EPHB2 gene leads to a major platelet functional defect. Blood. 2018; 132(19): 2067-77.

[51] Vaiyapuri S, Sage T, Rana RH, Schenk MP, Ali MS, Unsworth AJ, et al. EphB2 regulates contact-dependent and contact-independent signaling to control platelet function. Blood. 2015; 125(4): 720-30.

[52] Prevost N, Woulfe D, Tanaka T, Brass LF. Interactions between Eph kinases and ephrins provide a mechanism to support platelet aggregation once cell-to-cell contact has occurred. Proc Natl Acad Sci U S A. 2002; 99(14): 9219-24.

[53] Suzuki-Inoue K. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood. 2019; 134(22): 1912-8.

[54] Mammadova-Bach E, Gil-Pulido J. Sarukhanyan E, Burkard P, Shityakov S, Schonhart C, et al. Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived galectin-3. Blood. 2020; 135(14): 1146-60.

[55] Mammadova-Bach E, Zigrino P, Brucker C, Bourdon C, Freund M, De Arcangelis A, et al. Platelet integrin alpha6beta1 controls lung metastasis through direct binding to cancer cell-derived ADAM9. JCI Insight. 2016; 1(14): e88245.

[56] Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018; 11(1): 125.

[57] Bergstrand J, Miao X, Srambickal CV, Auer G, Widengren J. Fast, streamlined fluorescence nanoscopy resolves rearrangements of SNARE and cargo proteins in platelets co-incubated with cancer cells. J Nanobiotechnology. 2022; 20(1): 292.

[58] Yadav S, Storrie B. The cellular basis of platelet secretion: Emerging structure/function relationships. Platelets. 2017; 28(2): 108-18.

[59] Pokrovskaya ID, Joshi S, Tobin M, Desai R, Aronova MA, Kamykowski JA, et al. SNARE-dependent membrane fusion initiates alpha-granule matrix decondensation in mouse platelets. Blood Adv. 2018; 2(21): 2947-58.

[60] Boyd AW, Bartlett PF, Lackmann M. Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov. 2014; 13(1): 39-62.

[61] Janes PW, Vail ME, Gan HK, Scott AM. Antibody Targeting of Eph Receptors in Cancer. Pharmaceuticals (Basel). 2020; 13(5): 88.

[62] Corrado M, Giorgio C, Barocelli E, Marzetti GV, Cantoni AM, Di Lecce R, et al. Evaluation of the Anti-Tumor Activity of Small Molecules Targeting Eph/Ephrins in APC (min)/J Mice. Pharmaceuticals (Basel). 2020; 13(4): 69.

[63] Ferlenghi F, Castelli R, Scalvini L, Giorgio C, Corrado M, Tognolini M, et al. Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice. J Pharm Biomed Anal. 2020; 180: 113067.

[64] Giorgio C, Incerti M, Corrado M, Rusnati M, Chiodelli P, Russo S, et al. Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction. Biochem Pharmacol. 2018; 147: 21-9.

[65] Incerti M, Russo S, Corrado M, Giorgio C, Ballabeni V, Chiodelli P, et al. Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3alpha-carbamoyloxy derivative with antiangiogenetic properties. Eur J Med Chem. 2020; 189: 112083.

[66] Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, et al. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leuk Res. 2016; 50: 123-31.

[67] Killock D. Synergy of EphB2 and PD-1 blockade. Nat Rev Clin Oncol. 2022; 19(10): 616.

[68] Sadeghi S, Quinn D, Dorff T, Pal S, Groshen S, Tsao-Wei D. et al. EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. J Clin Oncol. 2022:JCO2102923.

[69] Jiang SH, Wang YH, Hu LP, Wang X, Li J, Zhang XL, et al. The physiology, pathology and potential therapeutic application of serotonylation. J Cell Sci. 2021; 134(11): jcs257337.

[70] Saponara E, Visentin M, Baschieri F, Seleznik G, Martinelli P, Esposito I, et al. Serotonin uptake is required for Rac1 activation in Kras-induced acinar-to-ductal metaplasia in the pancreas. J Pathol. 2018; 246(3): 352-65.

[71] Ye D, Xu H, Xia H, Zhang C, Tang Q, Bi F. Targeting SERT promotes tryptophan metabolism: mechanisms and implications in colon cancer treatment. J Exp Clin Cancer Res. 2021; 40(1): 173.

[72] Skolnik G, Bagge U, Dahlstrom A, Ahlman H. The importance of 5-HT for tumor cell lodgement in the liver. Int J Cancer. 1984; 33(4): 519-23.

[73] Skolnik G, Bagge U, Blomqvist G, Djarv L, Ahlman H. The role of calcium channels and serotonin (5-HT2) receptors for tumour cell lodgement in the liver. Clin Exp Metastasis. 1989; 7(2): 169-74.

[74] Schneider MA, Heeb L, Beffinger MM, Pantelyushin S, Linecker M, Roth L, et al. Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models. Sci Transl Med. 2021; 13(611): eabc8188.

RIGHTS & PERMISSIONS

2024 The Author(s). Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.